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Introduction: Polypharmacy has been a global threat these days and raised a question about 
its determinants. Differences in socioeconomic conditions, comorbid conditions, healthcare 
services use of individuals were expected to be related to Polypharmacy. Populations with 
cardiovascular diseases are more likely to be on multiple medications. However, no studies 
investigated the effects of socioeconomic differences and differences in healthcare use and 
multi-morbidity in the Russian middle-aged population. So, this study aims to determine the 
prevalence and determinants of Polypharmacy in two Russian cities. 
Materials and methods:  Data were collected in a cross-sectional Know You Heart study 
conducted in two big Russian cities from November 2015 to December 2017 (4051 
participants). The descriptive statistics for the socioeconomic factors, health care use, and 
multi-morbidity were presented using percentages, mean and standard deviations. Chi-square 
test was done to test the difference in proportions. Logistic regression models were used to 
study the association between study variables and Polypharmacy, and. Odds Ratios (OR) with 
95% confidence interval CI) were presented as the measures of association. 
Results:  Out of 4051 participants, 374 were on Polypharmacy. Participants on Polypharmacy 
were significantly older, were either overweight or obese (86%), with multimorbidity (80%), 
and used more health care services. 47% of them were above 65 years, 39% were at 55-64 
years, 10% were at 45-54 years and only 4% were at 35-44 years. These findings were 
confirmed by multivariable analysis. Relative to age group 35-44 years the OR and CI for age 
groups; 55-64 years and 65 years were 4.05(2.32-7.09) and 8.77(5.009-15.388) respectively; 
for obese relative to normal weight was 2.99(2.15-4.15); for multimorbid participants relative 
to one or less disease was 4.83(3.68-6.33) where p-trend was <0.001. Similarly, with OR and 
CI 6.30(4.49-8.85) and 7.72(1.62-36.67) for 5+ times of GP visits and hospitalization 
respectively relative to no GP visits or hospitalizations, was found that as increased numbers of 
times of GP visits and hospitalization increased odds of being on PP also increased. 
Conclusion: One out of ten of our sample was on Polypharmacy. Increasing age, body mass 
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With the increase in chronic diseases and the aging population globally, there is a rise in 
prescription of medications, or Polypharmacy (PP). As there is no exact definition, 
Polypharmacy, also known as multi-medication, can be explained as the use of multiple 
medications at a time to treat one or multiple conditions. Different studies have defined 
Polypharmacy as the use of multiple medications ranging from over five to over 11 at a time. 
Usually, the use of medication over five is considered Polypharmacy, and over 10 were 
considered hyper Polypharmacy or excessive Polypharmacy. (77) The prevalence of PP among 
different European countries ranges from 26.3% to 39.9%.(15) From 1995 to 2010, patients 
with Polypharmacy with medications ≥5 increased from 11.4% to 20.8%, and with medications 
≥10 increased from 1.7% to 5.8% (6) and within a decade, the use of multiple drugs and use of 
more than five drugs increased by 20% and 70% respectively in 2010. (7)  The prevalence rates 
over the world is considerably range from 10 % in Greek general population to 75% in 
Australian nursing care home. (75,76) 
1.1 Adverse health outcomes and Polypharmacy 
The use of multiple medications and the presence of multiple chronic conditions increases the 
therapeutic complexity for both health care professionals and patients. This results in adverse 
health outcomes, usually associated with a high chance of adverse effects, drug interactions, 
prolonged hospitalization, increased medication costs, and drug-related mortality.(1,2,3,4) The 
magnitude of harm could result from drug interactions and drug-disease interactions. In drug-
disease interactions, the worsening of another disease happens while taking medication for one 
condition. Usually, older adults above 50 with chronic diseases and multiple specialist 
physicians in long-term care facilities are the most risk groups for Polypharmacy with at least 
five medications daily. (5,23) As a result of an increasing number of older people living with 
multi-morbidity, the risk of adverse events and poor health outcomes increases. Polypharmacy 
also brings the worst-quality life, leading to medication-related symptoms, adverse effects, and 
other symptoms due to medication administration errors. (18) It is seen that Polypharmacy is 
one of the risk factors for hospital admission and residence in care homes. The length of a 
hospital stay and adverse drug effects also increase due to multiple medications. 
Although the causality between death and Polypharmacy is unclear, increased mortality is 
related to higher Polypharmacy. The meta-analysis of 47 studies showed a significant dose-
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dependent association between categorically defined medications (one to four, five, and six to 
nine medications) and mortality. (12) Polypharmacy has also shown that the risk of frailty in 
older adults, and co-occurrence of Polypharmacy and frailty led to poorer health outcomes. (30) 
Unplanned and drug-related hospitalization are due to inappropriate prescriptions and adverse 
effects of drugs. (13) Also, from a study among the people living with HIV in 24 countries, PP 
is associated with lower health-related quality of life outcomes, and most people prefer lesser 
medications. (15) 
1.2 Factors associated with Polypharmacy 
Different factors contribute to the Polypharmacy, such as physical inactivity, number of 
diseases, quality of life, socioeconomic factors, number of physicians involved, and abnormal 
body weight. These factors may directly or indirectly contribute to the high prevalence of 
Polypharmacy. For example, physicians may directly prescribe different medications for 
patients with multiple diseases if they think they need them. At the same time, factors that help 
increase the risk of diseases indirectly increase the risk of Polypharmacy. 
1.2.1 Age-sex  
Studies suggested that Polypharmacy varies according to age groups and gender.(4,13,15,16) 
An increase in age was seen to be directly related to Polypharmacy. As age increases, the 
disease burden also increases, leaving the complexity for treatments with different medications 
resulting in drug-related side effects, drug interactions, and drug adherence. (4,20,26,31,35) 
The only study estimating Polypharmacy prevalence in Russia found that Polypharmacy and 
multi-morbidity were associated and tended to increase the older population's Adverse Drug 
Reactions (ADRs). (26) The degree of exposure to Polyharmacy varies for men and women 
varies. Women were more likely to be at risk due to Polypharmacy than men and people living 
in urban areas than in rural areas. (19,20,44,48) The prevalence of comorbid conditions for both 
genders and differences in health-seeking behaviors were thought to be major factors 
contributing to Polypharmacy in different degrees.  
1.2.2 Socioeconomic conditions (Education and Income) 
Adverse socioeconomic conditions of patients may influence the choice of treatment by the 
physicians and increase the risk of Polypharmacy; the lower the income and education, the 
higher was the risk of Polypharmacy.(24,25,72,74) The patient's level of education and 
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knowledge about drug use have been significant factors related to Polypharmacy. Older adults 
with no or minimal educations are more likely to take multiple medications. Insufficient 
knowledge about medication use, adverse effects, and comorbidities in older patients might 
contribute to Polypharmacy (70,71). In a study in Sweden, the lower education level of 
participants increased the probability of Polypharmacy.(21,22,23). Patients with higher 
education tend to have more interaction with physicians and drugs-related information. This 
lowers the risk of being on PP. Population with low income are believed to be at greater risk of 
Polypharmacy. Different disease burdens due to poor socioeconomic conditions might put them 
at greater risk of PP. Whereas studies in Brazil and Sweden, people with higher income are also 
at greater risk as they can offer more healthcare services than low-income groups. (68,69,72,74) 
This trend put both income groups in different degrees of Polypharmacy. 
1.2.3 Multi-morbidity 
Polypharmacy is believed to be a clinical consequence of multi-morbidity generally in older 
adults. The multi-morbidity trends in different European countries are increasing, and this 
prevalence increases with age. (75) Multi-morbidity, the co-occurrence of at least two or more 
chronic conditions, is related to poor health outcomes and increased healthcare costs. Different 
diseases such as cardiovascular diseases (CVD), diabetes mellitus, chronic obstructive 
pulmonary disease (COPD), and dementia are associated with multi medications. Among them, 
PP is strongly associated with treatment for CVD as it is recommended by different 
international guidelines with complex regimens and combinations of drugs.(8) Due to this, 
patients with cardiovascular diseases are exposed to various medication-related burdens. About 
90% percent of people taking multiple drugs take medications that are active on the 
cardiovascular system.(9) Around the globe, CVD is one of the significant causes of death and 
disability. In 2015, age-standardized CVD mortality in Russia was 368.8 per 100,000 
population. Though CVD mortality started decreasing in 2003 in Russia, it is one of the leading 
causes of death.(11) 
1.2.4 Lifestyle factors 
Smoking, alcohol consumption, physical inactivity are the individuals' behaviors that contribute 
to PP. Usually, increased smoking and alcohol consumption and sedentary lifestyles are 
unhealthy behaviors believed to increase the Polypharmacy. All these factors increase the risk 
for multi-morbidity, thereby increasing the demand for more medications at a time. Older adults 
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with chronic diseases having unhealthy behaviors are the most vulnerable groups for exposure 
to Polypharmacy. (3,59,18,62) 
1.2.5 Health care service use 
Generally, clinical visits and hospitalizations tend to increase the number of medications. As 
any medical condition arises, healthcare-seeking behaviors increase, and the probability of 
using different health care services also increases. To combat the medical conditions, clinicians 
or any medical staff will prescribe or suggest the different medications. This could directly 
increase the chance of exposure towards Polypharmacy. Different studies had suggested an 
increase in the risk of Polypharmacy with an increase in the use of health care services. But a 
reverse impact is also seen as more medication increased the adverse effects and increased the 
need for hospitalization. (65,66) So, the knowledge about the association between the 
utilization of health care services and Polypharmacy is of great importance to minimize the risk. 
1.3 Motivation and aim of the study 
To achieve a good therapeutic outcome, along with the drug-related need of the patient, is 
challenging. There are increasing drug-related problems associated with inappropriate 
prescribing and adverse health outcomes. It is necessary to measure or assess the prevalence of 
PP from a clinical perspective since it can be a marker of multi-morbidity, adverse drug 
reactions, and inappropriate prescriptions. In 2017, WHO also mentioned Polypharmacy as a 
risk factor and concern for patient's safety and listed it as one of the three actions to reduce the 
severe avoidable harm related to multiple medications by 50% in 5 years.(10) From the public 
health perspective, it is essential to know the prevalence and factors related to Polypharmacy 
in the middle-aged population. In the case of multi-morbidity, it is essential to take multiple 
medications, but risks related to the concurrent use of different drugs must be calculated, or 
Polypharmacy should be avoided. (27,28) 
To the best of literature search, very little is known on the prevalence and determinants of PP 
in Russia's middle-aged population. The only identified study is based on a small number of 
participants.(26) Therefore, this study aims to report the prevalence of Polypharmacy in two 
Russian cities based on the Know Your Heart study. The relationship of Polypharmacy with 
socioeconomic characteristics and health care services use is likely to differ depending on the 
country's health care system characteristics. Therefore, it is of interest to look at how these 
variables relate to Polypharmacy in Russia. 
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This study aims : 
a) To determine the prevalence of Polypharmacy among the middle-aged population of two 
Russian cities and identify the association with socioeconomic factors (income, education), age, 
and sex. 
b) To assess Polypharmacy's relationship with cardiometabolic multi-morbidity, and use of 
health care services in Know Your Heart study. 
 
 
Research question: what is the difference in different socio-demographic factors, use of 
















2. Materials and methods 
2.1 Study population and design: 
Know your Heart study is a cross-sectional study of cardiovascular health in two big cities in 
Russia. The study was conducted as a baseline interview and followed by a health check at 
polyclinics (within 2 weeks). The baseline interview was conducted from November 2015 to 
December 2017 and included 5089 participants aged 35-69, of whom 4542 attended health 
checks.  
Three types of response percentage were calculated based on the outcome of every visit made 
to each address and the overall response percentage of the health check component were 67% 
in Arkhangelsk and 37% in Novosibirsk. This analysis will be based on 4051 participants (men 
and women) who attended the health check and answered the question about their current 
medication use. 
 
2.2 Data and Sample collection: 
A minimum of 3 attempts was made to get a response from each address. At the baseline 
interview, a trained interviewer administered a questionnaire using a computer-assisted 
personal interviewing device. The questionnaire includes sections on sociodemographic 
factors, physical activity, physical health (including health service use), and various self-
reported health measures.  The questionnaire also included questions about diet quality score, 
smoking, household structure, socioeconomic circumstances, and alcohol use. 
Health check included the questionnaire and physical examination of the cardiovascular system 
and was administered by either a nurse or a cardiologist. It included questions on past medical 
history. Participants were asked to bring all their medications with them during the health 
check, including inhalers, and names and doses used per day were recorded. A maximum of 7 
medications was recorded for each person.  
Physical examination included blood pressure measurements, anthropometry (height, waist and 






















Figure 1: flow diagram for the study population 
 
 
Baseline interview of middle-aged 
population of two Russian cities in 
between 2015-2017 
 
2381 participants from 
Arkhangelsk 
2161 participants from 
Novosibirsk 
Attended Health Check 
(4542) 
Final sample for analysis 
N=4051 
Did not answer question 
about their medication 
use N= 453 
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2.3 Study Variables 
2.3.1 Dependent Variable:  
Polypharmacy: Polypharmacy was defined as the self-reported use of 5 or more medications. 
The number of medications will be calculated based on the question, "Do you currently use any 
medications, including inhalers?" This question was asked only to health check participants. 
2.3.2 Independent Variables: 
2.3.2.1 Main exposures: 
- Age and Gender. Age was analysed as a categorical variable: 35-44 years, 45-54 years, 55- 
64 years and 65-69 years. 
- Education and income: In Know Your Heart study, participants answered a question: 'what 
is your level of education?' with 7 answer options. The responses result was further categorized 
into three levels as 1) incomplete secondary (incomplete secondary or lower), 2) secondary 
level ((complete secondary, professional school (without secondary degree, PTU), professional 
school and secondary (e.g., PTU and secondary education), Specialized secondary (e.g., 
medical, pedagogical college, technicum)) and 3) higher education levels (incomplete higher 
and higher)). 
The participants' income level was determined by asking a question, "Which of the phrases 
below best describes this household's financial situation during the past year?" The responses 
were grouped into three categories: 1) "There is not enough money for food or clothes and other 
items", 2) "enough money for food and clothes but it is difficult to buy large domestic 
appliances, a large new car, a flat or a 3) house" and 3) "we have no financial constraints." 
- Cardiometabolic multi-morbidity: Multimorbidity was defined as the co-occurrence of two 
or more of the following conditions: diabetes mellitus, stroke, heart failure, arterial fibrillation, 
angina, myocardial infarction, hypertension. These conditions were defined based on self-
report: during the baseline interview, participants were asked if doctors had ever told them if 
they had MI, stroke, or diabetes and if they were ever diagnosed with diseases such as 




Hospitalizations/physician visits: The number of hospitalizations in the past 12 months were 
asked and recorded in days. The number of general practitioner (GP) visits and number ofof 
hospitalization in the past 12 months were recorded. 
2.3.2.2 Confounders 
- Alcohol consumption and smoking: CAGE was used to screen for alcohol problems, and 
participants with a score >2 will be categorized as having alcohol problems (76). The question 
about current smoking was asked in the baseline questionnaire with response options: current 
smoker, non-smoker, and ex-smoker. 
- Biological markers 
BMI- Body Mass Index was calculated during the health check-up and was further divided into 
5 categories as <18.5, 18.5-24.9, 25.0-29.9, 30.0-34.9, and 35+. BMI from 25 to 29.9 was 
considered overweight and BMI over 30 as obese, whereas BMI from 18.8-24.9 was considered 
normal BMI and below 18.5 as underweight. 
Blood pressure- Systolic and diastolic blood pressure were measured using a device ((OMRON 
705 IT (OMRON Healthcare)), and the mean from the second and third recording was recorded 
in mmHg. 
Total cholesterol- From blood samples at the health check, total cholesterol level was measured 
using AU 680 Chemistry System Beckman Coulter device in the central laboratory and 
expressed in mmol/L. 
2.4 Statistical analysis:  
Statistical analysis were carried out using Statistical Package for Social Sciences (SPSS), IBM, 
version -27.  
Standard descriptive statistics were calculated for Polypharmacy as well as other study 
variables. Means were presented for continuous variables (BMI, Total cholesterol, HDL, LDL, 
SBP, DBP) and frequencies were be presented for categorical variables (Age, Sex, study site, 
Education level, financial situation, Smoking, Alcohol use, Use of any medication, Times of 
GP visits and Times of hospitalizations). 
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In bivariate analysis cross-tabulations for all study variables by Polypharmacy were conducted 
to compare frequencies of categorical variables with chi-square test for statistical significance. 
In addition, the differences in means between groups for continuous variables were tested using 
Student's T-test.  
To examine the association between age, sex, socioeconomic determinants (income and 
education), use of health care services, multi-morbidity and PP, the univariate logistic 
regression model was fit with each risk factor separately. Then in the multivariate analysis, 
logistic regression models were adjusted for age and sex, BMI, high blood pressure, total 
cholesterol, smoking, and alcohol use, diabetes. Those factors were chosen for adjustment 
because they are strongly related to both exposure and the outcome, and can potentially explain 
the observed univariate associations. 
The numbers of GP visits and number of hospital visits were additionally adjusted for multi-
morbidity.  
The analysis was based on complete cases (with no missing values on any covariate in the 
analysis). 
2.5 Ethical approval 
Ethical approval for the Know Your Heart study was obtained from the ethics committees of 
the London School of Hygiene & Tropical Medicine (approval number 8808), Novosibirsk 
State Medical University (approval number 75; 21 May 2015), the Institute of Preventative 
Medicine (approval received 26 December 2014), Novosibirsk and the Northern State Medical 
University, Arkhangelsk (approval number 01/01-15; 27 January 2015)29. This Master project 
was based on anonymized data and did not require approval from REK. 
Signed informed consent was obtained both at baseline interview and at the health check for all 
participants.  
2.6 Data Access 
Data access was given following an application to the database of "Know your Heart" study. 





3.1 Baseline characteristics of study sample: 
A cross-sectional study of 4504 participants at two Russian cities (Novosibirsk and 
Arkhangelsk) recruited a higher percentage of female (58%) participants compared to male 
(42%) participants (Table 1). The age range of the was 35 to 69 years old. The proportion of 
people aged in between 55-65 years (32%) was highest in comparison to other age groups; 35-
45 years (21%), 45-55 years (28%), and 65-69 years (18%). 
More than half of the sample (55%) had completed the secondary level of education, 41.5% 
had the higher level, and 3.5% had the incomplete secondary level. The average BMI of the 
population was 28.19 kg/m2, and cholesterol level was 5.54 mmol/L. Most of the population 
(76.5%) had enough money for food, clothes, and other items compared to those who did not 
have enough (19.4%), and the remaining (1.9%) had no financial constraints. More than half of 
the population (57%) said they used at least one medication the last month. The proportion of 
never smokers, current smokers, and ex-smoker were 49.5%, 25.2%, and 25.3%, respectively. 
In addition, 88.6% and 88.9% of the population had CAGE score of less than 2 (no alcohol-
related problems), and 40.7% of the population had two or more diseases (multi-morbidity). 
 Table 1. Descriptive characteristics of the study sample, N = 4504. 
Variable Name Mean (sd) or percent (N) Missing (N) 
Sex   
       Male, % 41.9% (1888)  
       Female, % 58.9% (2616)  
Age (at health check)   
      35-44 years 21.3% (958)  
      45-54 years 27.9% (1258)  
      55-65 years 32.3% (1457)  
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      65-69 years 18.5% (831)  
Site    
     Novosibirsk  47.6% (2142)  
     Arkhangelsk  52.4% (2362)  
Education level   
     Incomplete secondary (%) 3.4% (154)  
     Secondary (%) 55.2% (2486)  
     Higher (%) 41.4% (1864)  
   
BMI (kg/m2) 28.19 (5.64) 15 
   
Total cholesterol (mean, mmol/L) 5.54 (1.15) 70 
HDL-cholesterol (mean, mmol/L) 1.44 (0.36) 70 
LDL- cholesterol (mean, mmol/L) 3.73 (0.93) 70 
   
SBP (mean, mmHg) 2/3rd reading 132.72 (20.16) 356 
DBP (mean, mmHg) 2/3rd reading 83.09 (11.41) 356 
Financial situation  80 
   Not enough money for food, clothes and 
other items 
19.4% (874)  
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 Have enough money for food, clothes and     
other items 
76.9% (3465)  
     Have no financial constraints 1.9% (85)  
Use of any medication  453* 
      Yes 57.1% (2313)  
       No  42.9% (1738)  
Smoking  13 
      Never smoker, % 49.5% (2223)  
      Ex-smoker, % 25.2% (1133)  
      Current smoker, % 25.3% (1135)  
Alcohol (CAGE score)   
      <2 88.67% (3994)  
      ≥2 11.33% (510)  
Times of GP visits  3 
    0 45.6%(2056)  
    1 to 4 43.4(1955)  
    5+  10.9%(490)  
Times of Hospitalization   
    0 84.5%(3808)  
    1 to 4 15.3%(689)  
    5+ 0.2%(7)  
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Multi-morbidity     
     Presence of  one or less disease 59.3% (2672)  
     Presence of two or more diseases 40.7% (1832)  
   
 
3.2 Prevalence of Polypharmacy in the study sample: 
The overall prevalence of Polypharmacy was 9% i.e., 374 participants out of 4051, of which 
around 2/3rd were women (64%). As age increases the proportion of having Polypharmacy also 
increases; for 35-45 years, 45-54 years, 55-65 years and 65-69 years are 4%, 10%, 39% and 
47% respectively. Table 2 shows that higher proportion of participants with Polypharmacy were 
overweight (27.5%) and obese (58%), compared to people without Polypharmacy (overweight 
– 38%, obese – 30%).  Mean BMI was also higher in participants with Polypharmacy compared 
to those without Polypharmacy.  
People having secondary education level (56.15%) has the highest participants with 
Polypharmacy while with incomplete secondary level (8.83%) has least. Among participants 
with Polypharmacy, there was a smaller percent with higher education (35.0%) than those 
without Polypharmacy (41.3%). Also, for participants who have enough money (69.9%) for 
food, clothes, and other items are among the highest Polypharmacy compared to participants 
with the least financial constraints (2%). Higher percentage of those with polypharmacy have 
financial constraints (28.1%) compared to those without polypharmacy (18.4%) 
Table 2 also shows that 57.5% of participants with Polypharmacy did not smoke, while 24.34% 
were ex-smokers, and the rest (17.91%) were current smokers. Only a few (7.22%) participants 
with Polypharmacy were defined as problem drinkers by CAGE score of >=2, versus 12% in 
the group without Polypharmacy.  80% of the participants with Polypharmacy had at least two 
or more diseases compared to 36% among participants without Polypharmacy suggesting that 
prevalence of Polypharmacy increases with presence of comorbidities. 
Table 2 also suggested that as the number of visits to General Practitioner (GP) increases, the 
proportion of participants with Polypharmacy also increases. For five or more times of GP visits 
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maximum (40%), proportions of participants were with Polypharmacy compared to 8% without 
Polypharmacy. For numbers of hospitalizations also, as the number of hospitalizations 
increased, the proportion of participants with Polypharmacy increased compared to those 
without Polypharmacy. 
Table 2. The differences in CVD risk factors between participants with and without 






Sex   0.019 
      Male, % 36% (136) 42.64%(1568)  
      Female, % 64% (238) 57.36% (2109)  
Age (at health check)   <0.001 
      35-44 years 4%(15) 23.36%(859)  
      45-54 years 10%(37) 29.4%(1081)  
      55-65 years 39%(146) 31.82%(1170)  
      65-69 years 47%(176) 15.42% (567)  
Site     
      Novosibirsk  35.3%(132) 57.6% (2118)  
      Arkhangelsk  64.7%(242) 42.4% (1559)  
Education level   0.044 
     Incomplete secondary(%) 8.83%(33) 7%(255)  
     Secondary (%) 56.15%(210) 51.7%(1903)  
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     Higher (%) 35.02%(131) 41.3%(1519)  
    
BMI (kg/m2) 31.47(6.37) 27.81(5.43) <0.001 
BMI categorical   <0.001 
    Underweight(>18.5) 0 1.25% (46)   
    Normal(18.5-25) 13.9% (52) 30.86%(1135)  
    Overweight(25-30) 27.5% (103) 38%(1398)  
    Obese(30+) 58% (217) 29.89%(1085)  
Total cholesterol (mean, mmol/L) 5.08(1.22) 5.56(1.13) <0.001 
HDL-cholesterol (mean, mmol/L) 1.34(0.34) 1.45(0.36) <0.001 
LDL- cholesterol (mean, mmol/L) 3.35(0.95) 3.75(0.91) <0.001 
Triglycerides, (mean, mmol/L)    
SBP (mean, mmHg) 136.70(20.34) 132.33(20.08) <0.001 
DBP (mean, mmHg) 82.27(10.68) 83.21(11.49) 0.131 
Smoking   0.001 
    Never smoker, % 57.5% (215) 48.5% (1783)  
    Ex-smoker, % 24.34% (91) 25% (921)  
    Current smoker, % 17.91% (67) 26.25% (965)  
Alcohol (CAGE score)   0.007 
      <2 92.78% (347) 88% (3239)  
      ≥2 7.22% (27) 12% (438)  
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Financial situation   <0.001 
   Not enough money for food, clothes 
and other items 
28.1% (103) 18.4% (666)  
   Have enough money for food, clothes 
and other items 
69.9% (256) 79.5% (2881)  
     Have no financial constraints 2% (7) 2.1% (76)  
Numbers of GP visits   <0.001 
    0 17.9% (67) 48.6% (1786)  
    1 to 4 42% (157) 43.3% (1590)  
    5+  40.1% (150) 8.1% (299)  
Numbers of Hospitalization   <0.001 
    0 65.2% (244) 86.4% (3178)  
    1 to 4 33.7%(126) 13.5%(496)  
    5+ 1.1%(4) 0.1%(3)  
Multi-morbidity     <0.001 
     Presence of  one or less disease 20%(75) 64%(2355)  
     Presence of two or more diseases 80%(299) 36%(1322)  
    
*453 who did not answer the question about their medication use were excluded from the 
analysis.   
** P-values were obtained from the Pearson's chi-square test for categorical variables and 




3.3 Relationship between sample characteristics and Polypharmacy 
Table 3 summarizes the result of univariate and multivariate analysis of different factors 
associated with Polypharmacy. The prevalence of Polypharmacy was higher by 30% 
(OR=1.3;95% CI: 1.04-1.62) in women compared to men in the univariate analysis, but 
attenuated in the multivariate analysis adjusted for CVD risk factors(BMI, high blood pressure, 
cholesterol level, smoking and alcohol consumption). As age increases, the prevalence of 
Polypharmacy also increases. In univariate analysis all age groups 45-54 years (OR= 1.96; 95% 
CI:1.06-3.59), 55-64 years (OR= 7.14;95% CI: 4.17-12.27) and 65-69 years (OR=17.77; CI: 
10.30-30.43) were significantly associated with higher polypharmacy compared to the youngest 
age group (35-39). But in multivariate analysis, only age group 55-60 years (OR= 4.05; CI: 
2.32-7.09) and 65-69years (OR= 8.77; CI: 5.009-15.388) were significantly associated with an 
increase in Polypharmacy.  
In univariate analysis the prevalence of having polypharmacy increased by 50 % and 28 % with 
having incomplete secondary level of education (OR=1.50; 95% CI: 1.002-2.24) and secondary 
education level (OR= 1.28; 95% CI: 1.01-1.26), respectively compared with having higher 
education. While in multivariable analysis, the association doesn't seem to be significantly 
associated.  For financial situations, none of those subgroups were associated considerably with 
Polypharmacy in both univariate and multivariate analysis.  
In univariate analysis, multi-morbidity (two or more disease) was significantly associated with 
Polypharmacy (OR=7.102; 95% CI: 5.46-9.23). After adjusting for BMI, high blood pressure, 
cholesterol level, smoking and alcohol consumption in multivariable analysis, multi-morbidity 
was participants with multimorbidity had still 4.83 higher odds of polypharmacy  (OR= 4.83; 
95% CI: 3.68-6.33) compared to those who with one or less disease. 
In univariate analysis, times of GP and times of hospitalization in last 12 months were also 
significantly associated with an increase in Polypharmacy. The probability of having 
Polypharmacy increased by 2.63 times (OR=2.63; 95% CI: 1.96-3.53) for the group with 1 to 
4 GP visits and by 13.37 times (OR=13.37; 95% CI: 9.77-18.28) for the group with 5+ GP visits 
compared to no GP visits. After adjusting for BMI, high blood pressure, cholesterol level, 
smoking, alcohol consumption, and multi-morbidity, the prevalance Polypharmacy increased 
by 1.16 times (OR=1.16;95% CI: 1.22-2.33) and by 5.81 times (OR= 5.81; 95% CI: 4.06-8.31) 
respectively for (1 to 4) and (5+) GP visits.  
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Similarly, the increase in the number of hospitalizations was associated with an increase in 
Polypharmacy. For (1 to 4) times and 5+ of hospitalization, the odds of having Polypharmacy 
increased by 3.30 times (OR=3.30; 95% CI: 2.61-4.18) and 17.36 times (OR=17.36; 95% CI: 
3.86-78.03) respectively compared to no hospitalization. While adjusting for BMI, high blood 
pressure, cholesterol level, smoking, alcohol consumption and multi-morbidity in multivariate 
analysis, the association was still significant, i.e., for 1 to 4 times of hospitalization probability 
of Polypharmacy increased by 2.36 times (OR=2.36;95% CI: 1.80-3.09) and by 5.40 times 
(OR= 5.40; 95% CI: 1.00-29.18) respectively for (1 to 4) and (5+) times of hospitalizations. 
Table 3: The association of age, sex, education, income, use of health services, multi-
morbidity with Polypharmacy in Univariate and Multivariate logistic regression models.  
 Crude Odds Ratio 
(95% CI) 
p-value  Adjusted Odds 
Ratio (95% CI) 
p-value  
Sex   0.019  0.896 
      Male, % 1  1  
      Female, % 1.3(1.04-1.62)  1.01(0.77-1.34)  
Age (at health check)  <0.001  <0.001 
      35-44 years 1  1  
      45-54 years 1.96(1.06-3.59) 0.03 1.51(0.811-2.84) 0.191 
      55-65 years 7.14(4.17-12.27) <0.001 4.05(2.32-7.09) <0.001 





Education level  0.045  0.948* 
     Incomplete secondary (%) 1.5(1.002-2.24) 0.049 0.96(0.75-1.23) 0.76 
     Secondary (%) 1.28(1.01-1.60) 0.034 0.84(0.55-1.29) 0.44 
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     Higher (%) 1  1  
Financial situation    0.051* 
    Not enough money for food and 
clothes  
1.67(1.16-2.60) 0.205 1.43(0.62-3.28) 0.398 
    Have enough money for food 
and clothes 
0.96(0.44-2.11) 0.92 1.04(0.46-2.35) 0.917 
     Have no financial constraints 1  1  
Multi-morbidity      <0.001* 
     Presence of one or less disease 1 <0.001 1  
     Presence of two or more 
diseases 
7.102(5.46-9.22)  4.83(3.68-6.33)  
Times of GP visits    <0.001** 
    0 1    
    1 to 4 2.63(1.96-3.53) <0.001 1.69(1.22-2.33) 0.001 
    5+  13.37(9.77-18.28) <0.001 5.81(4.06-8.31) <0.001 
Times of Hospitalization    <0.001** 
    0 1    
    1 to 4 3.30(2.61-4.18) <0.001 2.36(1.80-3.09) <0.001 
    5+ 17.36(3.8-78.03) <0.001 5.40(1.00-29.18) 0.050 
 




**- adjusted for age, sex, BMI, high blood pressure, cholesterol level, smoking, alcohol 
consumption and multi morbidity. 
4. DISCUSSION 
This study sought to find the prevalence and determinants of Polypharmacy in the population 
of two Russian cities, Arkhangelsk and Novosibirsk. The prevalence of Polypharmacy in the 
study sample (35-69 years old) was 9.2%. Compared to the results of prevalence rates 
worldwide ranging from 10 % in the Greek general population to 75% in Australian nursing 
care home(75,76), this rate falls on the lower side. In other countries in Europe, the prevalence 
ranges from 26.3% to 39.9%(15) and an increasing trend was observed.(7)  I found that in the 
sample of oldest (65-69 years old) participants, the prevalence of Polypharmacy was high 
(47%) while in the youngest age group (35-44 years), it was just 4%.  
In this analysis, I focused on differences in socio-demographic factors, use of health care 
services, and comorbidities among participants with Polypharmacy and without Polypharmacy. 
It was observed that the prevalence of Polypharmacy was significantly related to age, sex, 
education, number of GP visits, number of hospitalizations, and multi-morbidity, but not with 
income. 
4.1 Age, sex and Polypharmacy 
In this study, as age increased, the prevalence of Polypharmacy also increased. Almost half 
(47%) of the participants with Polypharmacy were in the age group 65-69 old years. In 
univariate and multivariate analysis, the probability of having Polypharmacy also increased 
with age. In univariate analysis, with the increase in age above 65 years the likelihood of having 
Polypharmacy increased by almost 18 times compared to 35-39 years old participants.  But 
after adjusting for CVD risk factors (BMI, high blood pressure, cholesterol level, smoking and 
alcohol consumption), the likelihood dropped by almost half (8.77 times). Therefore, some 
higher risks of Polypharmacy in older age are due to the higher prevalence of CVD risk factors. 
Comparing the result with a similar setting in Russia was difficult as not many studies of PP 
were done in Russia. These results can be compared with a similar study in Switzerland and 
The United States (4,31). A study in Switzerland having almost the same setting as this study 
had the prevalence following the same trend of increasing from the age of 40 years and the 
likelihood of having Polypharmacy above the 65 years almost 10 times compared to the middle-
aged group of population. (4) Despite of large population, in the polish cross-sectional study, 
similar associations between age and PP were observed.  (38) These patterns over the different 
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parts of world suggests the higher prevalence in elderly specially above 65 years similar as in 
our study.  
Age is a risk factor for CVD; it was seen that many CVDs were present among most older 
adults compared to the general population (38,39), so the chance of cardiovascular-specific 
Polypharmacy would be high. In an Ethiopian study of cardiovascular outpatients, the 
prevalence of cardiovascular Polypharmacy for the elderly was almost double compared to 
another study for all outpatient's prescriptions in the same setting (16,37). Different cardiac 
conditions and the presence of other comorbidities with an increase in age can explain the 
increase in Polypharmacy in older adults. With the increase in cardiac comorbidities, 
prescriptions to alleviate these conditions resulted in increased Polypharmacy. (45,47) In 
different studies, it was also seen that elderly age was associated with Polypharmacy related 
side effects, adverse reactions, drug interactions, and poor drug adherence. (20,26,34,35,36) 
These results also support that the elderly group of the population is at high risk of 
Polypharmacy, with the associated risk of adverse effects and drug interactions. 
Sex was associated with Polypharmacy in the univariate analysis, but no significant association 
was seen in our multivariable analysis after adjustment for CVD risk factors. There were no 
consistent results in previous studies for gender and Polypharmacy. In many studies, females 
were more prevalent to Polypharmacy than male participants, though some results suggest male 
participants were more prominent to Polypharmacy than females (19,20,42,43,44,48,52,53). 
One study in Finland shows females using more prescription drugs than males, but another 
study in Saudi Arabia shows male participants are more likely to be exposed to Polypharmacy 
than females (42,43). In another review, males and females were exposed to many medications 
to a different degrees with the difference in their medical conditions (44). These could be 
explained by different comorbid conditions for both genders responsible for Polypharmacy. 
Prescription attitudes of physicians towards males and females and different socioeconomic 
gradients and their health-seeking behaviors could also be for such differences in the results 
(41). This also indicates that gender could affect Polypharmacy differently in different 
condition and the relationship could be subjective. In context of Russia, the association between 
polypharmacy and sex is interesting because of the huge gender gap in mortality – men have a 
much lower life expectancy than women(78). Attenuation of association between 
polypharmacy and sex after adjustment for CVD risk factors may indicate that study sample 




4.2 Comorbidities and Polypharmacy 
In this study, the probability for Polypharmacy increased by 7 times for participants with 2 or 
more disease conditions. While adjusting BMI, high blood pressure, high cholesterol level, 
smoking and alcohol as confounders for comorbidities in multivariable analysis, results still 
shows significant association. In multivariable analysis, the probability of being on 
Polypharmacy was almost 5 times (OR=4.83) for those with at least 2 or more diseases 
conditions. This was consistent with what was found in previous studies. (26,44,45,55,56,57) 
In a cross-sectional study in Canada, the prevalence of Polypharmacy increased for community-
dwelling adults with an increase in numbers of chronic disease conditions (56,57). In another 
study in the primary health care setting, the prevalence of Polypharmacy increased from 13% 
with one chronic illness condition to 33% with two chronic illnesses and up to 62% with three 
or more chronic conditions. (55) Also, another Russian study showed that elderly patients with 
comorbidities have a higher prevalence of Polypharmacy. (26) In all these studies, as age 
increased, the number of chronic conditions also increased, leading to more drug use.  
As cardiac conditions require multiple medications simultaneously to alleviate the condition 
and, with an increase in CVD risk factors (age and obesity), multi-morbidity such as diabetics, 
hypertension, hyperlipidemia also increases, requiring multiple treatments at the same time. 
(4,37,58) These could have potentially elevated the risk to be on Polypharmacy for patients 
with cardiovascular diseases with aging. Also, other conditions unrelated to cardiovascular 
conditions had contributed equally towards the Polypharmacy potentially risking the person on 
drugs related problems such as ADRs, drug reactions and drug adherences. (26,59,60) 
 
4.3 Hospitalization, Clinician visits and Polypharmacy 
As the number of times of GP visits and times of hospitalization increased, the tendency to be 
on Polypharmacy also increased in this study. The probability would be around 2.6 times and 
13.3 times more to be on Polypharmacy with 1 to 4 times , and five or more times of GP visits 
compared to no GP visits. In multivariable analysis, after adjusting comorbidities, smoking, 
alcohol consumption, BMI, high blood pressure and total cholesterol level, patients would be 
around 1.6 times and 5.8 times more potential risk on Polypharmacy with 1-4 times and, five 
or more times of GP visits. Similarly, for 1 to 4 and, five and more times of hospitalization, the 
risk to be on polypharmacy increased by 3.3 times and 17.3 times respectively. After adjusting 
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for comorbidities, smoking, alcohol consumption, BMI, high blood pressure and total 
cholesterol level, the risk drops to 2.3 times and 5.4 times, respectively. 
Recent studies have shown similar results, an increase in the utilization of health services was 
associated with the increase in Polypharmacy. (46,61,62) A cohort study in Italy showed 
Polypharmacy and excessive Polypharmacy are risk factors for emergency return and 
hospitalization.(65) Also, another observational study in Australia  among community-dwelling 
older men showed an association between all types of hospital admission with the number of 
used medication.(64)  As number of chronic diseases increased in a patient, the need of 
treatment (clinician visits and hospitalization) also could increase, resulting in a higher chance 
of Polypharmacy. This trend could also result from drug-related adverse reactions, drug 
interactions, and drug adherences while taking multiple medications. Drug-related 
hospitalization could result from the use of inappropriate prescriptions among older adults with 
the presence of risk factors such as change in pharmacokinetics and pharmacodynamics. (66) 
Multiple medications were also associated with a higher risk of unplanned hospitalizations. (67) 
Another study in Japan's primary care also showed the same results. Also, this study showed 
that patients consulting multiple numbers of the medical institution were on higher 
Polypharmacy compared to consulting with different practitioners of the same institutions. (63) 
This could be due to lack of time to physicians to review the prescriptions by another physicians 
and lack of communications between these institutions. An integrated electronic prescription 
method with easy access for physicians would solve these problems. 
 
4.4 Education and Income 
Generally, poor socioeconomic indicators were believed to increase medication use. But this 
study found no significant association between some socioeconomic gradients such as 
education and income with Polypharmacy in the analysis adjusted for CVD risk factors. Results 
of several other studies had shown associations in both directions. Studies in Brazil showed the 
positive association of Polypharmacy with higher income and health insurances. (68,69,70) 
This could be due to financially more affluent individuals having more access to healthcare 
facilities compared with low-income groups. Whereas some other studies had shown a negative 
association of income with Polypharmacy. (72,74) This could be explained due to the presence 
of many diseases with low socioeconomic position. Also, different studies showed the 
association of low education level with an increase in the probability of Polypharmacy 
(70,71,73). Patients' education level could also increase the awareness towards the 
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Polypharmacy and help to interact with physicians. Generally, for educated older adults, it was 
easy to know about the drugs information and more active on patient-physician interactions. 
These could lower the risk of Polypharmacy. (72) 
In our study, incomplete secondary education level and secondary level of education were 
significantly associated with an increase in Polypharmacy in univariate analysis. After adjusting 
for CVD risk factors in the multivariate analysis, the association was attenuated. This can be 
explained by the fact that participants with higher education had a better risk factor profile 
(lower blood pressure, never smoking, lower cholesterol, lower BMI) than participants in other 
education categories. Association of lower education with unhealthy behaviors, like unhealthy 
eating habits, physical inactivity, or smoking, alcohol use has been shown in many countries. 
In Russia, most population has access to health care services. Therefore we can suggest that 
observed inequality in Polypharmacy is mostly driven by behavioral risk factors prevalent in 
lower education groups. Interventions aimed at unhealthy behaviours among lower education 
groups would be beneficial by decreasing cardiometabolic multimorbidity, and therefore 
polypharmacy at last decades of life. Further studies of socioeconomic determinants on 














5. STRENGTH AND LIMITATIONS 
This study is one of a few studies examining the prevalence and determinants of Polypharmacy 
in Russia. It provides much-needed evidence of the high prevalence of Polypharmacy among 
middle-aged adults in Russia and factors related to it. Another strength is a larger sample size 
allowing providing sufficient statistical power. All medications were recorded as they were told 
to bring with them, which increases the study's reliability. Though no medication-specific study 
was conducted, medications used in Polypharmacy were classified according to ATC 
classification, so makes the results more valid. This standardized classification makes the 
comparison more reliable.  
Only up to 7 medications were recorded during the health check examination for each person. 
This could limit the study only to Polypharmacy with five or more medications. Getting 
information about more numbers would have helped to assess the prevalence of hyper 
Polypharmacy. Only income and education might not cover the entire socioeconomic status of 
the study population; besides, measurement error is very likely for both variables. As smoking 
and drinking behaviors being self-reported, there can be some bias or under-reporting. All 
diseases were also self-reported by participants, so might exclude or miss other potential 
diseases with maximum Polypharmacy. The health check component's overall response 
percentage was 67% in Arkhangelsk and 37% in Novosibirsk. This also can leave out 
participants with potential Polypharmacy and lead to selection bias.  An important limitation of 
this study is its cross-sectional design, therefore we could not establish whether the association 
between hospitalization and Polypharmacy was causal, and what explains this association – 
adverse drug reactions or need for more hospitalizations and medications for the treatment of 











This study shows just 9% of middle-aged adults from two Russian cities were exposed to 
Polypharmacy. A significant association between Polypharmacy with age, comorbidities and 
health care service utilizations were also seen. With the increase in age, the association also 
become stronger, suggesting older age with high chance of Polypharmacy. Education was 
associated with Polypharmacy in the univariate models, but not the income. A greater risk of 
being on Polypharmacy was also seen in groups with cardiometabolic multi-morbidity. In 
participants who visited general practitioners more often or were hospitalized more, the odds 
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